Pasithea Therapeutics Appoints Dr. James Lee to Scientific Advisory Board to Advance PAS-004 Development for Inflammatory Diseases

Pasithea Therapeutics (KTTA) has appointed Dr. James Lee, an expert in inflammatory bowel disease and the ETS2 pathway, to its scientific advisory board to advance the development of PAS-004, a MEK inhibitor, for treating inflammatory diseases like IBD. Dr. Lee's expertise is expected to guide the expansion of PAS-004's application beyond its current focus on neurofibromatosis type 1, with the company planning to fund this expansion through non-dilutive financing. Currently, PAS-004 is undergoing Phase 1 clinical trials for advanced cancer and NF1-associated conditions; however, forward-looking statements indicate uncertainty regarding the success of these trials.

Analysis

Pasithea Therapeutics (KTTA) has strategically strengthened its scientific advisory board with the appointment of Dr. James Lee, a distinguished expert in inflammatory bowel disease (IBD) and the ETS2 pathway, to guide the development of its lead drug candidate, PAS-004, for new indications. This move aims to leverage Dr. Lee's research, including a 2024 Nature publication identifying ETS2's role in inflammation and MEK inhibitors as effective suppressors, to expand PAS-004's application beyond its current Phase 1 trials in advanced cancer and neurofibromatosis type 1 (NF1) into ETS2 pathway inflammatory diseases like IBD. The company's plan to fund this expansion through non-dilutive financing, such as grants and strategic collaborations, signals an effort to advance research without immediate shareholder dilution, though it may also reflect caution in traditional equity markets or existing financial constraints. While Dr. Lee's appointment is a positive development for the scientific advancement of PAS-004, the company's forward-looking statements acknowledge inherent uncertainties in clinical trial success. Recent insider activity shows a minor sale by the CEO (960 shares for ~$792), and institutional holdings data from Q1 2025 indicates mixed sentiment, with four institutions adding shares (notably AdvisorShares Investments and Citigroup) and three decreasing positions, including complete exits by Armistice Capital (61,000 shares) and Morgan Stanley (1,000 shares). The overall sentiment for the announcement is moderately positive, though the market impact score is low, suggesting limited immediate market reaction.

Key Decisions for Investors

• Investors should view Dr. Lee's appointment as a positive step in de-risking the scientific development of PAS-004 for inflammatory diseases, but remain cognizant of the early-stage nature of these expanded indications and the inherent risks associated with clinical trials.
• Monitor Pasithea's progress in securing non-dilutive financing, as success in this area will be crucial for funding PAS-004's expanded development without impacting current shareholders through equity offerings, and observe upcoming clinical trial data for PAS-004 in both its existing and new indications.
• Given the mixed institutional investor activity, including significant exits, and the minor insider sale, a cautious approach is warranted; closely track further institutional movements and any substantial insider transactions for clearer sentiment signals.